Noxon
About
What does Noxon do?
Noxon Life Sciences is a biotechnology startup focused on developing novel therapeutics for inflammatory lung diseases. Their lead product candidate, 3-CP, is a nitroxide-based compound that has demonstrated significant potential in reducing airway inflammation and hyper-responsiveness in animal models of allergic asthma. The company aims to leverage the unique antioxidant properties of nitroxides to protect lung tissues and improve patient outcomes.
What is Noxon's revenue?
StartupHub estimates Noxon's annual revenue at $2.8M (range $683K to $4.2M, 27% confidence), based on comparable companies in the sector.
What is Noxon's valuation?
StartupHub estimates Noxon's effective valuation at $38.8M (range $25.0M to $60.0M, 21% confidence), based on comparable companies in the sector.
How much funding has Noxon raised?
Noxon has raised a total of $10M in funding. The most recent round on record is Seed.
Where is Noxon headquartered?
Noxon is headquartered in Cambridge, United States.
When was Noxon founded?
Noxon was founded in 2023.
What industry does Noxon operate in?
Noxon operates in Life Sciences, Biotech, Drug Discovery, HealthTech, Respiratory Health, Inflammation.
What is Noxon's current status?
Noxon's current operating status is: Inactive.
No comments yet. Be the first to share your take.